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Abstract Microarray technologies have both fascinated
and frustrated the transplant community since their intro-
duction roughly a decade ago. Fascination arose from the
possibility offered by the technology to gain a profound
insight into the cellular response to immunogenic injury
and the potential that this genomic signature would be
indicative of the biological mechanism by which that stress
was induced. Frustrations have arisen primarily from
technical factors such as data variance, the requirement
for the application of advanced statistical and mathematical
analyses, and difficulties associated with actually recogniz-
ing signature gene-expression patterns and discerning
mechanisms. To aid the understanding of this powerful
tool, its versatility, and how it is dramatically changing the
molecular approach to biomedical and clinical research, this
teaching review describes the technology and its applica-
tions, as well as the limitations and evolution of micro-
arrays, in the field of organ transplantation. Finally, it calls
upon the attention of the transplant community to integrate
into multidisciplinary teams, to take advantage of this
technology and its expanding applications in unraveling the
complex injury circuits that currently limit transplant
survival.
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Learning objectives
The purpose of this article was to review:
1. Microarrays, the basics
2. Evolution of microarray technology over time
3. The importance of microarrays in human biology
4. Microarray-based insights for the transplant physician
5. Current unmet biological questions in transplantation
and how can we use microarrays to address them
6. Methods of applying microarrays to clinical practice
7. Limitations of using microarrays in clinical practice
8. The black-box of microarray data analysis
Introduction
The completion of the human genome project has
revolutionized translational medicine. High-throughput
technologies, mapped to known target sequences, many
with known functions, now permit investigators to
interrogate the genome, transcriptome, proteome and
metabolome systematically, and to assess genomic muta-
tions, polymorphisms, epigenetic alterations, and micro-
RNAs. These technologies herald the potential for us to
translate their results into novel sensitive and specific
diagnostic tests and less toxic therapeutics, with the
anticipation of moving away from protocol-based
approaches to personalized medicine. In this new era,
investigators could potentially assess the molecular and
pathophysiological characteristics of individual patients
and their transplanted organs, tailor therapeutic regimens,
and administer them based on these profiles. One of the
key steps in this process will be the identification and
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e-mail: msarwal@stanford.eduvalidation of biomarkers. To date, microarray technologies
are, perhaps, the most successful and mature methodology
for high-throughput and large-scale genomic analyses.
Microarrays, the basics
Microarray technology is based on the principle of
complementary, single-stranded, nucleic acid sequences
forming double-stranded hybrids; thus, in essence, it is a
high-throughput Southern blot, where thousands of single-
stranded sequences that are complementary to target
sequences are synthesized, or spotted on to a small glass
or membrane support. The gene probes on the array are
either small (20–60 bp) single-stranded oligonucleotides,
synthesized in situ (provided by Affymetrix, Agilent), or
cloned complementary DNA (cDNA) amplified by poly-
merase chain reaction (PCR) and obtained by reverse
transcription of messenger RNAs (mRNAs). Illumina uses
designed oligonucleotide probes attached to beads that are
deposited randomly on a substrate. The selection of micro-
array platforms will have important effects in the later
stages, determining the complexity and flexibility of the
data to be analyzed. Care must be taken to choose a
platform that will allow data to be analyzed and dissem-
inated in the manners desired. Experimental design and
analysis are generally more straightforward with one-color
microarrays.
In organ transplantation, a prospective study of the gene-
expression profile of graft injury usually involves sample
collection from tissue biopsy, blood and biofluids, such as
urine, bile, or broncho-alveolar lavage, taken before, during,
and after injury. A schematic presentation of microarray
study is shown in Fig. 1. All collected samples are then
subject to standardized protocols for RNA extraction [1].
Routinely, one assesses RNA quality control by looking for
ribosomal RNA ratios of 260/280 >2. The integrity of the
RNA can also be assessed with Agilent 2100 Bioanalyzer,
using RNA Nano Chips (Agilent Technologies), where the
degradation of RNA can be determined by RNA integrity
number (RIN) [2, 3]. RNA amplification techniques are
often required for microarray analysis and are related to
downstream genetic analyses when small sample input is
used as starting material. Linear RNA amplification is a
strategy that has been used successfully to generate adequate
input RNA for molecular profiling studies. One method of
linear amplification, termed amplified antisense RNA
(aRNA) amplification [4], utilizes a T7 RNA polymerase-
based amplification procedure that allows quantitation of
relative gene expression levels from small tissue samples.
With modification of the classic Eberwine method, Wang et
al. [5] exploited a template switching effect at the 5′ end of
the mRNA transcript to ensure the synthesis of full-length
double-stranded cDNA. The most common aspects arising
from the use of sample amplification, irrespective of whether
the method confers linear or exponential amplification,
include amplification efficiency, 3′ bias and length of
aRNA/cDNA products, reproducibility, fidelity of maintain-
ing relative transcript abundance, benefits of the use of
amplified material versus non-amplified material, and dis-
advantages with amplification procedures [6].
RNA is next labeled with a detectable marker (fluores-
cent dye) and hybridized to an array containing individual
gene-specific probes, in either a dual-color (sample and
control pool with different colors, e.g. cDNA array) [7]o r
single-color (sample label only, e.g. oligonucleotide arrays)
hybridization system [8]. The array is hybridized with the
labeled sample(s) by incubation (usually overnight) and is
then washed to remove non-specific hybrids. A laser excites
the attached fluorescent dyes to produce light detected by a
scanner, which generates a digital image from the excited
microarray. The digital image is then processed by
specialized software to transform the image of each spot
into a numerical reading. This process finds the specific
spot location and shape, summarizes spot intensities, and
subtracts the surrounding background noise. To facilitate
the comparison between the experiments and to compensate
for differences in labeling, hybridizations and detection
methods, a data normalization step is usually performed.
This final numerical reading is proportional to the concen-
tration of the target sequence in the sample to which the
probe in the spot is directed. In competitive two-dye assays,
the reading is transformed to a ratio equal to the relative
abundance of the target sequence (labeled with one type of
fluorochrome) from a sample respective to a reference
sample (labeled with another type of fluorochrome). In the
one-dye technologies, the fluorescence is commonly yel-
low, whereas, in two-dyes technologies, the colors used are
green for reference and red for sample (although a replicate
using dye-swap is often done for quality control). The
appropriate choice of technology depends on experimental
design, availability and cost.
Evolution of microarray technology over time
Early microarray technology allowing the hybridization of
high-density cDNA with samples on nylon membranes
provided a technological step in the right direction, but this
technology is limited in scope by the nature of the matrix
supporting the clones. Two later innovations made possible
the new microarray technologies. One was the use of solid
supports, such as glass, which are much more amenable to
miniaturization and fluorescence-based detection [7]. The
second innovation was high-density oligonucleotides on
glass wafers using photolithographic masking techniques.
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has the key advantage that the oligonucleotides can be
synthesized at will, allowing chips to be manufactured
directly from sequence databases. Using this technology,
Affymetrix’s short-oligonucleotide array (HG_U133-
plus2.0) has became one of the most popular platforms
for research [9, 10]. Agilent has applied its ink printing
technology to microarrays, which has enabled high-speed
and quality production of oligonucleotide microarrays [11].
The Illumina BeadChip is a relatively new method with
increasing usage. The essential element of BeadChip
technology is the attachment of oligonucleotides to silica
beads. The beads are then randomly deposited into wells on
a substrate, such as a glass slide. The resultant array is
decoded to determine which oligonucleotide-bead combi-
nation is in which well [12]. More recently, Affymetrix
developed the GeneChip Exon Array, which offers a more
complete and accurate picture of overall gene expression by
enabling researchers to investigate the entire length of the
gene, not just the 3′ end. This exon-level analysis on a
whole-genome scale opens the door to the detection of
specific alternative splicing events that may play a central
role in disease mechanism and etiology. These arrays have
greater than 99% coverage of sequences present in the
RefSeq database, covering only well-annotated content
[13]. The evolution of microarray technology is summa-
rized in Table 1.
The overall differences in cDNA (e.g. Lymphochip) vs
oligonucleotide-based arrays (e.g. Affymetrix, Agilent) [14]
lie in the fact that the probe for cDNA arrays is 0.5–3k bi n
length, and it is 15–70 bp in length for the oligonucleotide
arrays. The oligonucleotide arrays can also perform
genotyping studies and detect splice variants, in addition
to mRNA profiling, but, unlike cDNA arrays, they require
multiple probes per target, with greater spot consistency
and less batch-to-batch variability.
The importance of microarrays in human biology
Microarray technologies were initially designed to measure
the transcriptional levels of RNA transcripts derived from
thousands of genes within a genome in a single experiment.
This technology has made it possible for one to relate
physiological cell states to gene-expression patterns for
studying tumors, disease progression, cellular response to
stimuli, drug target identification and transplant injury
mechanisms. For example, subsets of genes with increased
and decreased activities (referred to as transcriptional
profiles or gene-expression “signatures”) have been identi-
fied for acute lymphoblast leukemia [15], breast cancer
[16], prostate cancer [17], lung cancer [18], colon cancer
[19], multiple tumor types [20], organ transplantation [1],
and drug response [21]. Moreover, because the pool of
published data grows every day, integrated analysis of
several studies, or “meta-analysis”, have been proposed in
the literature [22]. These approaches detect generalities and
particularities of gene expression in diseases.
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research are not limited to gene-expression. DNA micro-
arrays are being used to detect single nucleotide poly-
morphisms (SNPs) of the human genome (Hap Map project)
[23], aberrations in methylation patterns [24], alterations in
gene copy number [25], alternative RNA splicing [26],
pathogen detection [27, 28] and micro-RNA [29].
Gene-expression profiles for prognostic classifiers are
usually built by the correlation of gene-expression patterns,
generated from specimens, with clinical outcome (e.g. acute
rejection vs stable without rejection). Gene-expression
predictive classifiers of response to treatment are generat-
ed by the correlation of gene-expression data, derived
from samples taken before treatment, with clinical and
pathological response to treatment. Although the identifi-
cation of the most relevant information from microarray
experiments is still under active research, well-established
methods are available for a broad spectrum of experimen-
tal set-ups. The analysis of gene-expression data at the
pathway and functional level, along with a systems
biology approach, will provide deeper insights into the
biological effects of complex disease states, such as in the
organ transplant milieu, and will improve risk assessment
of the same.
Microarray-based insights for the transplant physician
It is challenging to dissect any allograft injury mechanism
with single-gene studies because of the complexity of the
mechanisms for renal allograft rejection with different
immunosuppressive protocols and the spectrum of the
response with immunological injury. Previously researchers
have reported that expression of the cytotoxic molecules
granzyme B and perforin has been associated with rejection
and has been detected in blood [30], urine [31], and biopsy
tissue samples [32, 33] in human and experimental studies.
However, renal allografts transplanted into perforin or
granzyme A or B “double knockout” (gene deletion) mice
showed T cell-mediated rejection that was not mediated by
perforin or granzymes [34], indicating the redundancy of
the immune response during rejection.
The advent of microarray technology has enabled
researchers to detect the expression of thousands of genes
simultaneously, rather than measuring the expression of one
gene at a time, and has unlocked information about disease
heterogeneity that could not have been predicted by
standard clinical or pathologic criteria. Pioneering studies
of gene-expression profiles in breast cancer have identified
the molecular classification of breast cancer into clinically
relevant sub-types. This has provided new tools with which
one can predict cancer recurrence and response to different
treatments, and new insights into various oncogenic path-
ways and the process of tumor progression [35]. Subse-
quent microarray studies have changed the paradigm of
approach in lymphoma [36], where the diffuse B-cell
lymphoma was identified as having the worst prognostic
outcome, and in kidney transplantation, where rejection
sub-types with differential survival benefits and a prognos-
tic role for focal B-cell infiltrates was identified for
recalcitrant rejections [1]. Using cDNA microarrays,
Hauser and co-workers [37] have determined the gene-
expression patterns specific to living-donor vs deceased-
donor kidneys and suggest that suppression of specific
targets of inflammation in the deceased donor might be a
promising intervention for abrogating post-ischemic acute
renal failure.
These findings have brought a global paradigm shift
from traditional hypothesis-driven experiments toward
large-scale hypothesis generation and testing through
clinical trials. In the past few years, there has been an
increasing number of publications on solid organ trans-
plantation, with particular emphasis on the heart and
kidney. Supporting the results of earlier studies, micro-
arrays have also corroborated the finding of known path-
ways in rejection injury, such as evidence of the
dysregulation of the complement system [38, 39], inter-
leukins [40], anti-human leukocyte antigen (HLA) allo-
antibodies [41, 42] and solute transport genes [43], in
allograft rejection.
The interrogation of minimally invasive or non-invasive
biomarkers of graft injury has been more challenging than
the direct interrogation of the transcriptional changes in the
injured graft. Until recently, most gene-expression profile
Table 1 The evolution of microarray technology (n/a not applicable)
Type of array Number of probes
or probe sets
Target spots Manufacturer Year invented
Nylon 5,000 cDNA n/a 1996
Glass 40,000 cDNA Stanford 1996
Glass 54,000 25mer oligonucleotides Affymetrix 2000
Glass 46,000 60mer oligonucleotides Agilent 2004
Exon Array 1 million exons 123mer oligonucleotides Affymetrix 2005
BeadChip 50,000 79mer oligonucleotides Illumina 2005
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tional changes in peripheral blood during graft rejection
demonstrate significantly disparate gene-expression
changes from those of the inflamed graft, suggesting
that the local response to inflammation and injury in the
rejecting organ is highly localized. Additionally, the
intensity (fold-change) and quantity (number of signifi-
cant genes in rejection) of the rejection response in
peripheral blood is much smaller than the corresponding
response in the organ, even when biopsy and blood
samples from the same patient are examined simulta-
neously [44]( F i g .2). A recently published study [45, 46]
using both microarray and reverse transcriptase-polymerase
chain reaction (RT-PCR) to discriminate rejection from
non-rejection in peripheral blood samples from heart
transplant patients gave a reasonable correlation only with
severe and high-grade tissue rejection. Further, this was
only from samples taken later than 6 months after
transplantation, even though the risk of rejection is highest
during the first 6 months after transplantation [47]. When
biopsy predictor sets were used on blood samples, these
microarray data from blood did not give significant
predictions [47]. Despite these limitations of peripheral
blood sampling, efforts to examine this sample source for
clinical monitoring continue to hold promise. The answer for
increasing the sensitivity and specificity of biomarker
detection in peripheral blood may lie in the more careful
attention to improved methods of sample collection, storage,
and processing [44].
Conventional wisdom holds that long-term allograft
survival requires life-long immunosuppression. A tre-
mendous advance in peripheral blood monitoring for
immunosuppression customization may lie in the data
emerging from studies on a highly selected group of
organ transplant patients with spontaneous graft accep-
tance or prope tolerance in liver [48]a n dk i d n e y[ 49].
Blood gene-expression profiles from transplant patient
cohorts with tolerance, stable graft function and acute and
chronic graft injury, as well as peripheral blood samples
from healthy individuals, were analyzed on microarrays
[49]. A tolerance-specific signature of 49 genes was
identified in the kidney patients, which was strongly
regulated by transforming growth factor-beta (TGF-β)
signaling and cell cycle signaling. The tolerance signature
in immunosuppression-free liver patients included genes
encoding for gamma delta thymus (T)-cell and natural
killer (NK) receptors, and for proteins involved in cell
proliferation arrest. Importantly, 50% of kidney recipients
on steroid monotherapy, and 8% of kidney recipients on
triple-drug immunosuppression, also had the tolerance
signature, suggesting that those patients may benefit from
immunosuppression minimization [49]. We anticipate that,
after further validation studies, these biomarkers might be
useful as minimally invasive monitoring tools for guiding
immunosuppression titration and might provide novel
mechanistic insights into the acceptance mechanisms for
renal and liver allografts. As there is only a single gene
overlap between the renal and liver tolerance signatures,
we can hypothesize that either there is sufficient redun-
dancy in the system or there is some tissue (liver vs
kidney) specificity. Key array-based published studies
of transplantation are summarized in Table 2.
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T
G
B
2
,
H
A
-
1
,
C
O
R
O
1
A
,
I
G
K
C
,
R
A
R
R
E
S
3
,
C
C
L
5
,
H
L
A
D
R
B
3
,
S
T
A
T
1
,
C
1
Q
A
,
G
M
F
G
,
C
D
7
4
,
C
D
1
4
,
P
S
C
D
4
,
B
T
N
3
A
3
,
H
L
A
-
F
a
n
d
U
B
E
2
L
6
H
o
t
c
h
k
i
s
s
e
t
a
l
.
[
5
5
]
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
0
0
6
U
1
3
3
A
G
e
n
e
C
h
i
p
K
i
d
n
e
y
b
i
o
p
s
y
C
A
N
T
G
F
-
B
,
t
h
r
o
m
b
o
s
p
o
n
d
i
n
1
,
P
D
G
F
,
i
n
t
e
g
r
i
n
s
,
M
M
P
7
,
C
4
B
,
p
r
o
p
e
r
d
i
n
,
V
C
A
M
1
,
A
n
n
e
x
i
n
s
,
V
E
G
F
,
E
G
F
a
n
d
F
G
F
K
u
r
i
a
n
e
t
a
l
.
[
5
4
]
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
0
0
5
U
1
3
3
A
G
e
n
e
C
h
i
p
K
i
d
n
e
y
b
i
o
p
s
y
L
D
N
H
I
F
1
a
,
H
I
F
1
B
,
T
N
F
,
T
N
F
R
,
T
G
F
-
B
,
F
G
F
,
i
n
t
e
g
r
i
n
s
,
M
M
P
,
e
l
a
s
t
i
n
,
G
H
R
H
a
n
d
V
E
G
F
E
i
k
m
a
n
s
e
t
a
l
.
[
5
3
]
J
A
m
S
o
c
N
e
p
h
r
o
l
2
0
0
5
H
G
U
9
5
A
v
2
G
e
n
e
C
h
i
p
K
i
d
n
e
y
c
o
r
t
e
x
C
A
N
S
u
r
f
a
c
t
a
n
t
p
r
o
t
e
i
n
-
C
(
S
P
-
C
)
,
S
1
0
0
c
a
l
c
i
u
m
-
b
i
n
d
i
n
g
p
r
o
t
e
i
n
A
8
(
S
1
0
0
A
8
)
,
S
1
0
0
A
9
a
n
d
i
m
m
u
n
o
-
g
l
o
b
u
l
i
n
g
e
n
e
s
M
e
l
k
e
t
a
l
.
[
6
2
]
K
i
d
n
e
y
I
n
t
2
0
0
5
c
D
N
A
K
i
d
n
e
y
c
o
r
t
e
x
R
e
n
a
l
a
g
i
n
g
N
A
D
H
d
e
h
y
d
r
o
g
e
n
a
s
e
,
A
P
O
,
k
y
n
u
r
e
n
i
n
a
s
e
P
A
H
,
d
y
n
e
i
n
,
C
L
D
N
8
,
M
M
P
7
,
f
i
b
u
l
i
n
,
t
e
n
a
s
c
i
n
,
C
S
P
G
2
,
S
E
R
P
I
N
A
3
,
i
m
m
u
n
o
g
l
o
b
u
l
i
n
s
,
s
o
m
a
t
o
s
t
a
t
i
n
r
e
c
e
p
t
o
r
,
T
H
Y
1
,
n
a
t
r
i
u
r
e
t
i
c
p
e
p
t
i
d
e
r
e
c
e
p
t
o
r
a
n
d
S
L
C
s
o
l
u
t
e
t
r
a
n
s
p
o
r
t
e
r
f
a
m
i
l
y
Z
h
a
n
g
e
t
a
l
.
[
9
2
]
C
l
i
n
T
r
a
n
s
p
l
a
n
t
2
0
0
4
H
G
U
9
5
A
v
2
G
e
n
e
C
h
i
p
L
y
m
p
h
o
c
y
t
e
S
t
a
b
l
e
t
r
a
n
s
p
l
a
n
t
M
e
m
b
r
a
n
e
-
t
y
p
e
m
a
t
r
i
x
m
e
t
a
l
l
o
p
r
o
t
e
i
n
a
s
e
1
,
S
H
3
b
i
n
d
i
n
g
p
r
o
t
e
i
n
,
M
E
A
6
,
T
O
B
f
a
m
i
l
y
4
,
R
B
P
2
,
I
L
-
1
A
,
A
r
g
i
n
i
n
o
s
u
c
c
i
n
a
t
e
s
y
n
t
h
e
t
a
s
e
,
B
r
a
i
n
a
n
d
n
a
s
o
p
h
a
r
y
n
g
e
a
l
c
a
r
c
i
n
o
m
a
,
N
S
G
-
x
,
h
V
H
-
5
a
n
d
E
o
s
i
n
o
p
h
i
l
C
h
a
r
c
o
t
-
L
e
y
d
e
n
c
r
y
s
t
a
l
p
r
o
t
e
i
n
M
a
n
s
f
i
e
l
d
e
t
a
l
.
[
1
4
]
A
m
J
T
r
a
n
s
p
l
a
n
t
2
0
0
4
c
D
N
A
K
i
d
n
e
y
b
i
o
p
s
y
A
R
s
u
b
-
t
y
p
e
s
M
I
P
-
1
,
C
C
R
5
,
C
X
3
C
R
1
,
D
A
R
C
,
S
C
Y
B
1
0
,
S
C
Y
A
5
,
S
C
Y
A
3
,
S
C
Y
A
1
3
,
S
C
Y
A
2
,
I
L
2
R
B
,
I
L
6
R
,
I
L
1
6
,
1
L
1
5
R
,
D
E
F
A
1
,
D
E
F
B
1
,
S
C
Y
A
2
,
S
C
Y
A
5
,
M
S
T
1
,
S
T
A
T
1
,
S
T
A
T
6
,
C
D
6
9
,
M
A
L
,
N
F
A
T
C
3
,
A
n
n
e
x
i
n
s
,
C
A
S
P
1
0
,
P
E
C
A
M
1
a
n
d
V
C
A
M
1
H
a
u
s
e
r
e
t
a
l
.
[
3
7
]
L
a
b
I
n
v
e
s
t
2
0
0
4
c
D
N
A
K
i
d
n
e
y
b
i
o
p
s
y
D
o
n
o
r
s
o
u
r
c
e
C
o
m
p
l
e
m
e
n
t
s
,
L
T
F
,
N
K
4
,
V
C
A
M
1
,
i
n
t
e
r
l
e
u
k
i
n
s
,
H
L
A
,
B
C
L
6
,
G
P
X
2
,
F
B
P
1
,
P
C
K
2
,
S
O
R
D
,
A
P
O
A
4
,
C
Y
P
3
A
7
,
F
A
B
P
1
,
A
P
O
M
,
C
Y
P
3
A
4
,
H
I
F
1
A
,
S
T
A
T
1
,
T
I
M
P
1
,
A
D
A
M
T
S
1
,
T
N
F
S
F
1
0
a
n
d
C
D
C
2
5
B
K
a
i
n
z
e
t
a
l
.
[
9
3
]
A
m
J
T
r
a
n
s
p
l
a
n
t
2
0
0
4
c
D
N
A
K
i
d
n
e
y
b
i
o
p
s
y
D
o
n
o
r
s
o
u
r
c
e
O
s
t
e
o
p
o
n
t
i
n
,
S
O
D
2
,
R
A
R
R
E
S
1
,
c
h
e
m
o
k
i
n
e
l
i
g
a
n
d
1
,
a
n
t
i
l
e
u
k
o
p
r
o
t
e
i
n
a
s
e
,
S
T
A
T
1
,
C
D
H
6
,
S
P
P
1
,
S
E
R
P
I
N
A
3
a
n
d
G
P
X
2
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a
b
l
e
2
(
c
o
n
t
i
n
u
e
d
)
A
u
t
h
o
r
J
o
u
r
n
a
l
A
r
r
a
y
t
y
p
e
T
i
s
s
u
e
P
h
e
n
o
t
y
p
e
K
e
y
f
i
n
d
i
n
g
s
F
l
e
c
h
n
e
r
e
t
a
l
.
[
5
6
]
A
m
J
T
r
a
n
s
p
l
a
n
t
2
0
0
4
(
a
)
O
l
i
g
o
n
u
c
l
e
o
t
i
d
e
K
i
d
n
e
y
b
i
o
p
s
y
C
A
N
,
d
r
u
g
e
f
f
e
c
t
T
G
F
B
,
T
N
F
A
,
P
D
G
F
,
I
C
A
M
,
V
C
A
M
1
,
i
n
t
e
g
r
i
n
B
,
M
C
P
-
1
,
C
C
R
2
,
M
P
I
-
3
B
,
M
H
C
,
M
M
P
,
T
I
M
P
1
,
R
A
N
T
E
S
,
V
E
G
F
,
c
o
l
l
a
g
e
n
I
I
I
,
A
n
g
i
o
t
e
n
s
i
n
I
I
r
e
c
e
p
t
o
r
,
T
S
P
a
n
d
F
N
1
F
l
e
c
h
n
e
r
e
t
a
l
.
[
9
4
]
A
m
J
T
r
a
n
s
p
l
a
n
t
2
0
0
4
(
b
)
H
G
U
9
5
A
v
2
G
e
n
e
C
h
i
p
K
i
d
n
e
y
b
i
o
p
s
y
,
p
e
r
i
p
h
e
r
a
l
b
l
o
o
d
A
R
A
I
F
,
C
D
1
4
,
C
D
1
6
3
,
C
D
2
,
C
D
3
D
,
C
D
4
8
,
C
D
5
3
,
c
h
e
m
o
k
i
n
e
s
,
i
n
t
e
r
l
e
u
k
i
n
s
,
C
1
q
,
i
m
m
u
n
o
g
l
o
b
u
l
i
n
s
,
I
N
F
G
,
T
C
R
T
N
F
,
a
n
d
H
L
A
D
o
n
a
u
e
r
e
t
a
l
.
[
5
7
]
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
0
0
3
c
D
N
A
a
r
r
a
y
C
A
N
A
Q
P
2
,
A
Q
P
3
,
l
i
p
o
p
r
o
t
e
i
n
l
i
p
a
s
e
,
P
M
L
-
2
,
N
a
p
s
i
n
1
,
p
r
e
c
u
r
s
o
r
,
F
l
o
t
i
l
l
i
n
-
1
,
T
y
p
e
I
V
c
o
l
l
a
g
e
n
a
s
e
,
H
e
p
a
t
o
c
y
t
e
g
r
o
w
t
h
f
a
c
t
o
r
a
c
t
i
v
a
t
o
r
i
n
h
i
b
i
t
o
r
,
R
I
G
-
l
i
k
e
7
–
1
,
M
E
C
I
-
1
,
P
G
E
R
,
T
E
M
8
,
M
H
C
c
l
a
s
s
I
,
C
1
s
a
n
d
i
m
m
u
n
o
g
l
o
b
u
l
i
n
s
H
i
g
g
i
n
s
e
t
a
l
.
[
7
6
]
M
o
l
B
i
o
l
C
e
l
l
2
0
0
4
c
D
N
A
C
o
r
t
e
x
,
m
e
d
u
l
l
a
,
p
a
p
i
l
l
a
r
y
t
i
p
s
,
N
o
r
m
a
l
I
d
e
n
t
i
f
y
p
a
t
t
e
r
n
s
o
f
g
e
n
e
e
x
p
r
e
s
s
i
o
n
i
n
d
i
s
c
r
e
t
e
p
o
r
t
i
o
n
s
o
f
t
h
e
n
o
r
m
a
l
k
i
d
n
e
y
S
a
r
w
a
l
e
t
a
l
.
[
1
]
N
E
n
g
l
J
M
e
d
2
0
0
3
c
D
N
A
K
i
d
n
e
y
b
i
o
p
s
y
,
p
e
d
i
a
t
r
i
c
s
A
R
,
C
A
N
,
D
T
a
n
d
i
n
f
e
c
t
i
o
n
T
C
R
,
H
L
A
c
l
a
s
s
I
I
,
H
L
A
c
l
a
s
s
I
,
i
m
m
u
n
o
g
l
o
b
u
l
i
n
s
,
l
a
c
t
o
t
r
a
n
s
f
e
r
r
i
n
,
c
h
e
m
o
k
i
n
e
s
,
C
D
2
0
,
C
D
3
4
,
I
G
F
1
R
,
T
N
F
R
,
M
S
T
1
,
N
K
4
,
d
u
f
f
y
a
n
t
i
g
e
n
/
c
h
e
m
o
k
i
n
e
,
r
e
c
e
p
t
o
r
,
S
T
A
T
1
,
T
G
F
R
1
,
g
r
a
n
z
y
m
e
A
,
p
e
r
f
o
r
i
n
,
I
L
2
R
,
C
D
5
3
,
l
y
m
p
h
o
t
o
x
i
n
,
l
y
m
p
h
o
t
o
x
i
n
R
,
N
F
K
B
1
,
C
D
5
9
,
I
F
N
G
R
1
a
n
d
a
n
n
e
x
i
n
s
S
c
h
e
r
e
r
e
t
a
l
.
[
5
8
]
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
0
0
3
H
G
U
9
5
A
v
2
G
e
n
e
C
h
i
p
K
i
d
n
e
y
b
i
o
p
s
y
C
A
N
K
e
r
a
t
i
n
t
u
m
o
r
s
u
p
p
r
e
s
s
o
r
c
a
n
d
i
d
a
t
e
7
,
O
S
9
(
A
P
R
I
L
)
,
G
-
p
r
o
t
e
i
n
g
a
m
m
a
7
,
p
r
o
t
e
i
n
/
c
e
l
l
a
d
h
e
s
i
o
n
m
o
l
e
c
u
l
e
-
l
i
k
e
,
G
R
B
2
-
a
s
s
o
c
i
a
t
e
d
b
i
n
d
i
n
g
p
r
o
t
e
i
n
1
,
a
n
d
P
R
L
R
C
h
u
a
e
t
a
l
.
[
9
5
]
A
m
J
T
r
a
n
s
p
l
a
n
t
2
0
0
3
c
D
N
A
K
i
d
n
e
y
b
i
o
p
s
y
A
R
/
a
n
e
m
i
a
H
b
-
z
e
t
a
,
H
b
-
b
e
t
a
,
H
b
-
a
l
p
h
a
2
,
F
O
L
R
2
,
F
O
L
R
3
,
C
A
H
1
,
i
m
m
u
n
o
g
l
o
b
u
l
i
n
s
,
G
P
X
1
,
a
n
d
l
a
c
t
o
t
r
a
n
s
f
e
r
r
i
n
Z
h
a
n
g
e
t
a
l
.
[
9
6
]
T
r
a
n
s
p
l
a
n
t
P
r
o
c
2
0
0
2
O
l
i
g
o
n
u
c
l
e
o
t
i
d
e
L
y
m
p
h
o
c
y
t
e
S
t
a
b
l
e
t
r
a
n
s
p
l
a
n
t
C
D
8
0
,
i
n
t
e
r
l
e
u
k
i
n
s
,
C
D
4
4
,
C
D
4
0
L
,
C
D
4
0
,
V
L
A
-
5
,
L
F
A
-
1
,
T
C
R
a
l
p
h
a
,
L
c
k
,
c
a
l
c
i
n
e
u
r
i
n
,
P
K
C
,
I
F
N
G
,
L
F
A
-
1
,
T
C
R
a
l
p
h
a
,
L
c
k
,
c
a
l
c
i
n
e
u
r
i
n
,
P
K
C
,
I
F
N
G
,
T
G
F
B
,
T
N
F
-
a
l
p
h
a
,
T
N
F
R
1
,
G
-
C
S
F
R
a
n
d
P
D
G
F
r
e
c
e
p
t
o
r
,
A
k
a
l
i
n
e
t
a
l
.
[
9
7
]
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
0
0
1
H
u
6
8
0
0
G
e
n
e
C
h
i
p
K
i
d
n
e
y
b
i
o
p
s
y
A
R
H
u
M
i
g
,
T
C
R
R
I
N
G
4
,
I
S
G
F
-
3
,
C
D
1
8
A
n
i
m
a
l
s
t
u
d
i
e
s
K
u
s
a
k
a
e
t
a
l
.
[
9
8
]
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
0
0
7
A
g
i
l
e
n
t
r
a
t
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
a
r
r
a
y
G
4
1
3
0
A
K
i
d
n
e
y
a
l
l
o
g
r
a
f
t
s
,
T
l
y
m
p
h
o
c
y
t
e
s
B
r
a
i
n
d
e
a
t
h
d
o
n
o
r
G
r
o
1
,
I
P
-
1
0
,
p
5
3
,
N
F
k
a
p
p
a
B
,
M
y
c
,
J
u
n
,
c
-
f
o
s
,
L
C
N
2
a
n
d
S
P
P
1
B
e
r
t
h
i
e
r
e
t
a
l
.
[
9
9
]
K
i
d
n
e
y
I
n
t
2
0
0
6
2
3
0
A
G
e
n
e
C
h
i
p
K
i
d
n
e
y
a
l
l
o
g
r
a
f
t
s
C
A
N
M
M
P
-
1
1
,
-
1
2
,
-
1
4
,
A
D
A
M
-
1
7
,
T
I
M
P
-
1
,
-
2
T
G
F
-
B
,
M
M
P
-
9
,
m
e
p
r
i
n
a
n
d
M
M
P
-
2
4
D
j
a
m
a
l
i
e
t
a
l
.
[
1
0
0
]
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
0
0
5
m
o
u
s
e
s
t
r
e
s
s
t
o
x
i
c
i
t
y
G
E
A
r
r
a
y
K
i
d
n
e
y
a
l
l
o
g
r
a
f
t
s
C
A
N
A
N
X
A
5
,
C
A
S
P
1
,
C
A
S
P
8
,
T
N
F
R
I
I
,
T
R
A
I
L
,
F
A
S
L
,
B
A
X
,
i
n
d
u
c
i
b
l
e
n
i
t
r
i
c
o
x
i
d
e
s
y
n
t
h
a
s
e
,
c
y
t
o
c
h
r
o
m
e
p
4
5
0
4
A
,
[
a
l
p
h
a
]
-
c
r
y
s
t
a
l
l
i
n
e
B
,
h
e
m
e
-
o
x
y
g
e
n
a
s
e
I
I
,
S
O
D
,
H
S
P
6
0
,
H
S
P
2
7
,
B
C
L
-
X
a
n
d
m
e
t
a
l
l
o
t
h
i
o
n
e
i
n
S
c
h
u
u
r
s
e
t
a
l
.
[
1
0
1
]
A
m
J
T
r
a
n
s
p
l
a
n
t
2
0
0
4
O
l
i
g
o
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how can we address them?
Whilst great advances have been made in the discovery of
putative biomarkers in transplantation, disappointingly few
have been translated into clinically applicable assays; much
of this is due to a lack of well-designed clinical validation
studies. The most important challenge is having well-
designed validation and varying endpoint definitions. To
adapt molecular endpoints from single-gene studies as
representative of a particular mechanism of toxicity/injury
often assumes that a postulated mechanism must be known
beforehand, and this may result in “over-fitting” of the data,
making the inference not entirely accurate.
Chronic allograft nephropathy what are the early
injury pathways?
Chronic graft injury, potentially an indolent immune
response resulting in slow deterioration of organ function,
characterized pathologically in the kidney by tubular
atrophy, interstitial fibrosis, and fibrous intimal thickening
of the arteries, has a relatively transcriptionally homoge-
neous response of tissue fibrosis, when investigated at the
time of the established injury [1]. Although there is a
general consensus on the patient criteria for chronic
allograft nephropathy (CAN), it is not universal. Despite
the many presumed triggers for this injury (alloimmune
responses, donor age and tissue quality; brain death;
preservation/reperfusion injury; post-transplantation and
systemic stresses in the recipient environment) [50], early
injury triggers that could provide drug targets for manipu-
lation of injury progression have not been identified in
cross-sectional human studies. Animal models, where
injury mechanisms can be segregated better, have been
useful to study [51], but careful design of clinical trials to
ascertain longitudinal and evolutionary studies on graft
injury may be required. Given the difficulty of recipient
consent for multiple post-transplantation biopsies, the
discovery of biomarkers specific to CAN has been
challenging. Most of the published reports (Table 2) are
from a single sample time point [52–55]. However, with
careful study design, controlled studies have been per-
formed using sequential (paired) patient samples [56–58].
These studies are limited by relatively small sample size,
non-standardized protocol biopsies, and few sample collec-
tion time points; perhaps the field will be led by organs
where performance of these protocol biopsies is almost
standard of care, e.g. heart and lung transplantation.
Additional issues that would be important in the design of
clinical validation studies for biomarkers would be: a
prospective nature of sample identification, also allowing
for samples that could be then used for prediction of the
clinical events, maintaining homogeneity of patient sub-
groups and disease pathology, similar immunosuppression
regimes and controlling for patient demographics and the
use of other concomitant treatments.
The limitations of microarray studies and the importance
of well-designed validation strategies have been demon-
strated by microarray applications in cancer. In an attempt
to predict prognoses of cancer patients on the basis of
previously published DNA microarray studies, re-analysis
of data from the seven largest published studies showed that
the list of genes identified as predictors of prognosis was
highly unstable; the selection of training sets strongly
affected molecular signatures [59], and biomarkers from
the training sets did not perform as well in independent
validation studies. The most important challenge in
translational transplantation research is the lack of a true
gold standard for the classification of disease in organ
transplantation. The current histologic classification of
deteriorating organ transplants has many limitations,
including arbitrary cut-off points and poor inter- and
intra-observer reproducibility. This makes identification of
informative samples sets very difficult, resulting in the
difficult generation of microarray-based hypotheses in
transplantation.
Acute rejection prediction and immunosuppression
customization
Acute rejection (AR) depends on an orchestrated immune
response to histocompatibility antigens expressed by the
grafted tissue. The redundancy of AR mechanisms and the
problems with peripheral blood transcriptional analysis
(outlined above) has made it difficult for reliable bio-
markers to be developed for prediction of allograft rejection
and its outcome, irrespective of immunosuppression usage,
concomitant infection, recipient age or organ type. The
delineation of AR from antibody-mediated rejection (AHR,
also termed humoral rejection) is still debated. Though
effector mechanisms primarily responsible for the rejection
process classically involve activation of effector T cells and
memory T cells, alternative mechanisms of acute rejection
also recruit (to varying degrees) B-cells, natural killer cells,
eosinophils and neutrophils, antibody-mediated rejection is
currently thought to play a role in approximately 33% of
AR episodes [42]. Thus, though numerous markers of
different biologic pathways have been evaluated as diag-
nostic and prognostic tools to serve this purpose in human
[47, 56] and animal organ transplantation [60, 61], no
biomarkers have become firmly established for prediction
of acute rejection. It is unlikely that a single biomarker will
meet all clinical needs, such as non-invasive diagnosis and
prediction of transplant rejection and survival, given the
clinical confounders in the recipients’ post-transplantation
1650 Pediatr Nephrol (2009) 24:1643–1659environment. Microarrays may, over time, offer multiple
markers as gene-based tests, and combining these with the
genes found for graft tolerance [49] may enhance future
patient monitoring and enable individualized risk-adapted
patient care.
Limited donor source—how can we expand this?
Finding ways to use kidneys more effectively for transplan-
tation has the potential to extend the donor pool using dead
donors who meet the Standard Criteria for Donation (SCD)
as well as those from Expanded Criteria Donors (ECDs),
created by the United Network for Organ Sharing in 2002.
Higher-risk donor organs, once considered unsuitable, could
also be transplanted safely. With regard to higher-risk donor
organs, the question remains: Are all kidneys from older
donors equivalent with regards to biological and cellular
health? An array-based analysis of kidneys from a wide
spectrum of ages (8 months to 80 years) [62] suggested that,
though older kidneys appeared to have increased extracel-
lular matrix turnover and a non-specific inflammatory
response, combined with a reduction in processes depen-
dent on energy metabolism and mitochondrial function,
these results did not always correlate with chronological
age. Extension of expression data into hypothesis testing
for correlation studies of older kidneys with good vs poor
“transcriptional health” with post-transplantation function,
may offer a means to potentially expand the donor pool. To
date, these studies have not been performed.
Methods of applying microarrays to clinical practice
Identification of differentially expressed genes between
sample groups
Identifying whether genes have increased or decreased in
expression between two or more groups of samples is the
most common and basic type of analysis and provides a
simple characterization of the specific molecular differences
that are associated with a specific biological phenotype.
Using power analysis, it is possible to estimate the number
of samples required to identify a high percentage of truly
differentially regulated genes between sample groups.
Unsupervised analysis [63] is a useful means to assess, a
priori, the inter- and intra-group differences or similarities.
Unsupervised analysis is based on the assumption that co-
expressed genes have the potential to be regulated by same
transcriptional factors or to have similar biological func-
tions. Examples of unsupervised analysis methods are
hierarchical clustering [64], R (http://cran.r-project.org),
the Gene Expression Profile Analysis Suite (GEPAS) [65],
The Institute for Genomic Research (TIGR) T4 [66, 67],
GeneSpring [68] and Genesis [69]. Typically, genes are
represented on the y-axis, whereas samples are drawn on
the x-axis, and a dendrogram on each axis shows the degree
of relatedness of samples and genes to each other. A color-
coded matrix (heat map), where samples and genes are
sorted according to the results of the clustering, is used to
represent the expression values for each gene in each
sample and is the basis of many of the published microarray
figures. Though fold-change in fluorescence intensity
(expressed as the logarithm (base 2 or log2) of the sample
divided by the reference), is often used descriptively, it fails
to ascertain the true significance of small but significant
changes in gene-expression levels. Univariate analysis
measures of significance are preferred, e.g. for data sets
with normalized distribution, the t-test and analysis of
variance (ANOVA) test can be used, and for data without
normalized distribution, the Wilcoxon or Mann–Whitney
tests are often used. Another commonly used measure of
significance testing is significance analysis of microarrays
(SAM) (http://www-stat.stanford.edu/~tibs/SAM/). It
should be pointed out that the methods given in this review
are a selection from many others possible.
(a) Determining biomarkers for clinical phenotypes of
disease
The identification of gene-expression “signatures” asso-
ciated with diseases categories is called biomarker detection
or supervised classification. As the biomarker panel needs
to be predictive of disease class or clinical outcome,
learning and validation sets of samples are required, making
the sample size relatively large for this type of analysis.
Prediction analysis of microarrays (PAM, http://www-stat.
stanford.edu/~tibs/PAM/) is a powerful tool that can be
adapted for this use. The selection of a unique list of
genes by this approach does not, in and of itself, offer
sufficient knowledge for one to understand the biology of
a given system, suggesting the necessity to incorporate
biological knowledge into array analysis. Recent approaches
to microarray analysis address the limitations of convention-
al bioinformatics approaches by enriching the analysis with
knowledge of biological processes [70]. This approach has
the advantage over classical bioinformatics approaches that
the feature selection step can be performed based on data
that are completely independent of the clinical samples
used for the analysis. This strategy is very promising,
especially in disease states that are not easily classified into
clear distinct categories, as is the case in clinical transplan-
tation. Some ways to do this are either to use commercially
available software (Ingenuity Pathway Analysis: http://
www.ingenuity.com/; Pathway Studio: http://www.ariadne
genomics.com/) or to use hypergeometric enrichment
analysis from published data sets of biologically relevant
experiments [1, 49].
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Biomarkers that correlate with survival times are a very
important objective in the analysis of microarray data.
Selected genes can be combined with clinical classes and
incorporated into regression models to detect variations in
survival times using both the Kaplan–Meier method and
statistical tests. An example of this is shown where the
gene-expression microarray data for different molecular
rejection groups (AR-1, AR-2, and AR-3) [1] segregate by
the performance for recovery of graft function 4–6 weeks
after treatment intensification for the rejection episode
(Fig. 3). Different linear regression models can be tested
with independent variables (time, drug levels, and graft
function) and dependent variables (genes) to ascertain any
association between gene-expression and clinical variables.
(c) Other applications of microarrays in clinical practice
Commercially available microarrays can detect single
nucleotide polymorphisms (SNPs), which are an important
tool for identifying genetic loci linked to complex disorders
[71]. Unfortunately, the number of SNPs covered by the
array-based methods is fewer than 1% of the known SNPs
deposited in the public databases. Altered methylation
patterns in genomic DNA can also be identified by
microarrays, by the use of methylation-sensitive restriction
enzymes to generate fragments enriched with either
unmethylated or methylated CpG sites. Epigenetic phe-
nomena, such as cytosine methylation, histone acetylation
and phosphorylation, control the activation and deactivation
of genes, such that genes methylated in their promoters can
become inactive and can predispose individuals to cancers
[67]. Chromatin immune-precipitation (ChIP-on-chip)
assays [72, 73] can allow the estimation of alterations in
the expression of transcription factors in several diseases
(e.g. c-Myc is known to be differentially expressed in a
variety of cancers [74]). Pathogen specific microarrays
have been generated [27, 28] and can allow the direct
interrogation of specific pathogens on an array-based
platform.
What limits the use of microarrays in clinical practice?
Gene-expression profiling studies of renal transplantation
are highly complex, and the successful execution of such
studies requires close collaboration between physicians,
molecular biologists and bioinformatictists. The most
important challenge is the lack of a true gold standard for
the classification of disease in organ transplantation. The
current histologic classification of deteriorating organ
transplants has many limitations, including arbitrary cut-
off points and poor inter- and intra-observer reproducibility.
The classical approach to microarray analysis, which starts
with the identification of genes that differentiate between
two sample groups, depends on the assumption that distinct
disease entities exist and that we know, with certainty, what
these classes are. While the cancer literature may be able to
rely on disease classification based on outcome data, the
situation in organ transplantation is much more complicat-
ed, with many overlapping disease processes occurring
simultaneously. If microarray analysis in clinical transplan-
tation starts with a classification based on a flawed clinical
gold standard, the results of the microarray study will not
be any better than histologic examination and may even be
misleading. Currently, there is no simple solution to this
problem.
– Quality control
The high-throughput nature of this technology, com-
bined with the expected large numbers of data, result in a
high risk for error. With the increasing use of genomic
studies in transplantation, there is a need to control for
various confounder effects that obscure biomarker discov-
ery in graft rejection. In view of many concerns raised, the
US Food and Drug Administration (FDA) lunched the
Microarray Quality Control (MAQC) project. An excellent
correlation of gene expression of human reference RNA
(Stratagene) and human brain reference RNA (Ambion),
across seven different array platforms, across five different
laboratories, using three different amplification protocols
[75], was shown in this study. Thus, while the need for
quality control is a limitation for array studies, recognition
of means to address this could turn this around as a benefit,
resulting in the generation of robust datasets that could be
queried with confidence by multiple users.
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Fig. 3 Correlation between AR sub-type and graft outcome. Analysis
of the recovery of graft function over time revealed that grafts with
AR that were clustered in the AR-I transcriptional sub-group had
significantly poorer functional recovery than those classified as either
AR-II or AR-III [1]( P=0.02). P values were calculated from Kaplan–
Meier survival analysis. Data are for grafts with incomplete functional
recovery in the analyses according to sub-type of AR, where 80% of
AR-1 and ∼40% of AR-II had incomplete recovery of serum
creatinine to baseline values 6 weeks after treatment of the rejection
episode. All AR-III episodes recovered graft function by the same
definition
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At present, because of the sophistication of microarrays,
this is a costly technology available only in selected
laboratories. Microarray technologies, however, are rapidly
improving, and the costs of the technique continue to fall,
thus paving the way for wider access and more generalized
usage.
– Sampling variability
Particularly for renal transplant biopsies, differing
amounts of cortex vs medulla represented in a sample can
affect the pattern of gene expression of a sample. Therefore,
one can cross-reference a publicly available gene list
specific for different compartments of kidney to minimize
false clustering of samples [76]. There is also the problem
of variable sample pathology. If only one biopsy core is
being used for microarray analysis, it will be necessary to
identify transcriptional changes that are more global and
robust than patchy cellular interstitial infiltration, such as
effects of cytokines on the renal tissue or global interstitial
changes. mRNA is a very fragile molecule that can be
degraded within minutes of surgical procedure [77],
drastically affecting the interpretation of microarray data
[78]. Moreover, subtle variations in biopsy handling and
method of RNA extraction from samples can result in
different levels of gene expression [78].
– Difficulty in detecting some disease processes in
transplantation by microarrays
Existing collagen, readily visible to the pathologist, is
not necessarily associated with mRNA changes if the
process of active fibrogenesis is complete. Small cell
populations that make a major contribution to disease
might give only a weak signal in transcriptome studies of
whole biopsies or unseparated blood. Antibodies produced
in lymphoid tissues could damage the kidney without any
mRNA being detectable in the kidney. Microarray analysis
cannot offer insights into these critical cellular and
molecular processes in the tissues.
– Discrepancy in array studies
Weak overlap exists between gene lists from individual
studies of similar phenotypes in transplantation. The
disparity among microarray data can be attributed to several
factors: differences in microarray platforms with differing
gene sets; weak statistical power and small sample sizes;
biological variance because of variability in patient charac-
teristics; experimental variance including lack of uniform
protocols for study design, sample collection, RNA
processing, and sample labeling and hybridization; different
tools for data processing and statistical analysis (Table 3);
variable thresholds for data filtering; varying stringencies
for false discovery rates and statistical significance; and
different data analysis methods. Nevertheless, a recent
study compared microarray data for rejection across plat-
forms, samples, and laboratories with some success. A gene
set for acute rejection prediction generated from a heart
biopsy [47] was used to predict previous published data for
kidney biopsy [1, 56] and lung broncho-alveolar lavage
cells [79].
– Confounders exist in microarray experiments
Previous studies have demonstrated that the abundance
of globin genes in whole blood may mask the underlying
biological differences in whole-blood samples. In a com-
parison of gene-expression profiles of peripheral blood,
using different protocols of sample preparation, amplifica-
tion and hybridization on the Affymetrix platform, we
demonstrated that the globin reduction method is not
sufficient to unmask clinically relevant, rejection-specific,
transcriptome profiles in whole blood. Additional mathe-
matical application for globin gene depletion improves the
efficacy of globin reduction but cannot remove the
confounding influence of globin gene hybridization [44].
Other problems of analysis of blood may be more serious
than the globin issue: the massive changes in cell
populations caused by illness, surgery or infection make it
difficult to define small changes in specific mRNA levels. It
will be challenging to distinguish the blood signal for the
alloimmune response from such common non-specific
changes.
The black-box of microarray data analysis
All published microarray studies should be made publicly
available through the internet, on proprietary websites and
in public microarray database repositories, and should
generally follow the minimum information about a micro-
array experiment (MIAME) compliance format [80]o r
microarray gene-expression markup language (MAGE-ML)
[81].
Many freely available software tools are now available
for microarray data analysis. Though not completely
intuitive, they have extensive manuals that can take a
relatively inexperienced user towards the rapid understand-
ing of their application for data analysis, ranging from
image analysis, visualizations, differential expression, prin-
cipal component analysis, clustering, classification, regres-
sion and survival analysis. Examples of some of these
selected analytical methods are:
– The Gene Expression Profile Analysis Suite (GEPAS;
http://www.gepas.org)
– The Institute for Genomic Research (TIGR; http://
www.tigr.org/software/microarray.shtml)
– Significance analysis of microarrays (SAM; http://
www-stat.stanford.edu/tibs/SAM/),
– Prediction analysis of microarrays (PAM; http://www-
stat.stanford.edu/tibs/PAM/),
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www.ebi.ac.uk/expressionprofiler),
– Bioconductor (http://www.bioconductor.org),
– Cancer gene expression data analyzer (caGEDA; http://
bioinformatics.upmc.edu/GE2/GEDA.html),
– Analysis of microarray data (AMIADA; http://dambe.
bio.uottawa.ca/amiada.asp),
– GenePattern (http://www.broad.mit.edu/cancer/soft
ware/genepattern/),
– Genesis (http://genome.tugraz.at/Software/Genesis/
Description.html)
A comprehensive discussion of different analytical
strategies for microarray analyses are beyond the scope of
this review.
The annotation of probes on microarrays is problematic
for data analysis, which is shown in a particular commercial
microarray design in which the number of probes associ-
ated with a given gene changes over time. These changes
concern approximately 5% of the probe sets across the
history of annotation releases over a 2-year span [82]. For
Affymetrix Mouse 430 A/B, 13,699 out of 45,000 probes
changed gene names from 2003 to 2004, and 2,277 (5%)
probes changed annotation by their Entrez Gene identifiers
[82]. Similarly, in human array platforms, e.g. for the HG-
U133plus Affymetrix chip, unreliable representative public
identifiers were seen for 18.2% [83] of the probes.
Probe redundancy is an additional problem (each transcript
is probed by multiple oligonucleotide probes). This could
p o t e n t i a l l yb ec a u s e db ya na n n o t a t i o np r o b l e m ,w i t ha tl e a s t
5% of misannotation in each generation of the platform [82],
e.g. multiple probes may assign to multiple genes or a single
probe may map to multiple genes or Entrez IDs. The attention
of manufacturers should be drawn to the maintenance of
annotation accuracy and to the reduction of the number of
probes required for each gene, attempting to choose the most
representative probe/s. In addition, different portions of probe
sets contained unreliable representative public gene IDs, with
multiple genome hits. Harbig et al. [84] recently reassigned
the probe sets on the Affymetrix platform, on the basis of
each 25-mer probe sequence, and found that a large
percentage of probe sets did not actually bind fully to a
gene. They concluded that the set of probes assigned to be an
official probe set is a problem with the Affymetrix platform.
This is also a significant problem that may also be an issue
with the other platforms, i.e. the sequence of a gene changes
as additional information becomes available.
There are also different levels of detection (background
over noise) for probes or probe sets, with specific criteria
for each platform, which can have an impact on down-
stream analyses. Some of the different criteria used for a
probe detection for different array platforms are discussed:
Agilent cut off, absolute value of log2 red channel/green
channel >0.5 for at least one array; cDNA mean of channel
1 intensity/media background intensity >1.5, and/or nor-
malized mean of channel 2 intensity/media background
intensity >1.5; Affymetrix using a perfect-match-only
model, the value for each probe or probe sets are extracted
after background subtraction.
The exiting tools for converting the probe ID between
microarray platforms are very limited. The difficulty in
Table 3 List of pitfalls in microarray analyses and solutions (SVD singular value decomposition, Cy cyanine, qPCR quantitative polymerase
chain reaction)
Pitfalls in microarray analysis Solutions
Data variability, particularly for genes with low expression levels Use replicate arrays to reduce false positives
Small sample amounts which limit replication Use of amplified RNA (aRNA)
Expression bias due to amplification Use improved protocols with single-roundamplification
Difficult to control input RNA amounts accurately Use of normalization standard and two-color labelingstrategy
to minimize
Spot quality may vary Use stringent data-filtering criteria to assess signal/noise ratio
and spot signal consistency
Lot-to-lot variation in PCR yield on cDNA arrays Use data-filtering methods such as SVD to reduce batch biases
(see text)
Hybridization efficiency varies with different probes Use long-oligonucleotide arrays to minimize selected
hybridization artifacts
Unequal labeling efficiency of Cy3 and Cy5 dyes Use reciprocal labeling to confirm observations or use
single-dye labeling system
Small numbers of samples and very large numbers of genes analyzed
may contribute to false discovery
Confirm mRNA measurements using independent test methods
such as qPCR and independent samples
Heterogeneity within study groups may contribute to false discovery Use statistical modeling such as logistic regression to combine
multiple genes
Protein expression levels and function not measured Conform with protein expression methods
(e.g. immunohistochemistry, protein arrays)
1654 Pediatr Nephrol (2009) 24:1643–1659reusing data lies with the mapping of probes to established
gene identifiers. Therefore, microarray results need to be re-
evaluated periodically with the latest probe annotations.
Most recently, a tool (Array Information Library Universal
Navigator, AILUN, http://ailun.stanford.edu/) was devel-
oped by a Stanford University group that re-annotates all
gene-expressions/proteomics data from the Gene Expres-
sion Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/),
which is a public repository for gene-expression and other
high-throughput experimental data covering numerous plat-
forms and species. The AILUN server builds a universal
identifier ID table by relating all probe IDs to Entrez Gene
IDs on a monthly basis, and it is the first tool available that
allows researchers to compare microarray data across
different platforms and map genes across species [85]. It
also provides an opportunity for further discovery of
complicated disease processes using more samples that
have been deposited in GEO. The choice of processing
method has a major impact on differential expression
analysis of microarray data [86]. Some statistical issues
should be given consideration in data analysis, such as class
comparison, class prediction and class discovery [87].
When microarray data are being compared, various factors
influence the agreement between studies, such as different
technologies and platforms, statistical analysis criteria,
protocols, and laboratory variability [88].
Conclusions
High-throughput DNA microarray technology has been
increasingly applied in kidney transplantation to classify
molecular sub-types, to predict outcome and the response to
treatment, and to identify novel therapeutic targets. Al-
though results hold promise, this technology will not have a
full impact on routine clinical practice until there is further
standardization of techniques and optimal clinical trial
designs to set up higher volume validation studies for the
generated biomarkers. Owing to substantial disease hetero-
geneity and the number of genes being analyzed, collabo-
rative, multi-institutional studies are required to accrue
enough patients for sufficient statistical power. Customized
arrays or multiplex PCR for informative biomarkers can
then be applied to the clinics for event prediction, treatment
stratification, immunosuppression customization and im-
proved graft and patient survival.
Our scientific environment is ripe for research-based
implementations of integrative tools that support knowl-
edge-based data mining. This integration can provide the
cornerstone of research in the coming years. Developments
in this area will require close interdisciplinary collaboration
and will lead not only to the integration of data and
knowledge, but also to computer-supported experiments
and to knowledge generation platforms, thereby closing the
loop of data gathering, hypothesis generation and hypoth-
esis testing.
Questions
(Each question can be either true (T) or false (F). Answers
appear after the reference list)
1. Microarrays: the basics
(a) Microarrays are gridded probes on glass slides
(b) Microarrays consist of complementary DNA or
synthesized oligonucleotides
(c) cDNA arrays consist of short probes 20–60 bp in
length
(d) Oligonucleotide arrays use a common reference
and use two-color hybridization schema
2. The importance of microarrays in human biology lies in
our ability to use them for
(a) doing polymerase chain reactions
(b) genotyping by checking for single nucleotide
polymorphisms
(c) searching for changes in the copy number of
certain genes, specifically in cancers
(d) assessing peptide mass
3. Microarray studies in transplantation have revealed to
date that
(a) there is molecular heterogeneity in acute graft
rejection
(b) there are many differences in the etiologies of
chronic graft injury
(c) B-cells can play a critical role in the rejection
process and outcome
(d) biomarkers can be used potentially for immuno-
suppression minimization
4. Limitations of using microarray in clinical practice lie
in the following areas
(a) ease of analysis
(b) lack of hybridization specificity of cDNA arrays
(c) problems with annotation of gene names on array
platforms
(d) no need to amplify human samples
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